<DOC>
	<DOCNO>NCT01405963</DOCNO>
	<brief_summary>The purpose study ass late asthmatic response , safety tolerability AMG 157 follow multiple intravenous ( IV ) dose administration subject mild atopic asthma .</brief_summary>
	<brief_title>Double-blind , Multiple Dose Study Subjects With Mild Atopic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Male female subject history mild atopic asthma 18 60 yearsofage Body mass index ( BMI ) 18 35 kg/m2 Normal clinically acceptable physical examination ( PE ) , clinical laboratory value , ECG ; clinically acceptable PE include history mild atopic asthma Used inhaled shortacting Î²2agonists infrequently treat asthma No current exposure allergen subject experience asthmatic response No lung disease , exacerbation asthma low respiratory tract infection least 6 week prior screen Positive skin prick test common aeroallergens screen Additional inclusion criterion apply History evidence clinically significant disorder ( include psychiatric ) , condition disease would pose risk subject safety interfere study evaluation , procedures completion ; History current medical condition contraindicate methacholine challenge , myocardial infarction stroke within previous 3 month , know cardiac disease , uncontrolled hypertension aortic cerebral aneurysm Evidence active suspect bacterial , viral , fungal parasitic infection within past 6 week Subject know type I/II diabetes History residential exposure tuberculosis positive PPD QuantiFERON test within 4 week randomization Subject history malignancy type within 5 year prior enrollment Subjects test positive drugs/alcohol nicotine use screen Subjects test positive HIV , Hep B Hep C Additional exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Amgen</keyword>
	<keyword>AMG 157</keyword>
	<keyword>Asthma</keyword>
</DOC>